At its meeting of 30 January 2023, the Transparency Council adopted Opinion No. 9/2023 on the legitimacy of changing the reimbursement category of medicinal products containing trastuzumab in the form of an intravenous (IV) formulation.
Publication with the minutes of the Transparency Council meeting